SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of ...
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of ...
Expanded Functionality to Support COVID-19 Research Immediately Available Through Early Access “ROSALIND offers powerful data analysis capabilities and a unique ability to facilitate collaboration ...
Regular statin users and colorectal cancer (CRC) prognosis. Neoadjuvant chemoradiotherapy (NCRT) using concurrent S-1 and irinotecan in rectal cancer: Impact on long-term clinical outcomes and ...
A comparison of the burden of thyroid cancer amongst European Union 15+ countries, 1990-2017: Estimates from the Global Burden of Disease Study. This is an ASCO Meeting Abstract from the 2021 ASCO ...
NanoString plans to use its IPO proceeds to commercialize the nCounter analyzer and Prosigna test.--Courtesy of NanoString Fresh off the launch of its gene-expression cancer diagnostic, Seattle's ...
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results